First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis

Various anaplastic lymphoma kinase inhibitors (ALKIs) have been approved for first-line use in treating anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). To date, no head-to-head comparison of these newer generation ALKIs has been made, and different efficacies of ALKIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Kuan-Li, Chen, Hsiao-Ling, Tsai, Ying-Ming, Lee, Tai-Huang, Chang, Hsiu-Mei, Tsai, Yu-Chen, Chuang, Cheng-Hao, Chang, Yong-Chieh, Tu, Yu-Kang, Yang, Chih-Jen, Hung, Jen-Yu, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509704/
https://www.ncbi.nlm.nih.gov/pubmed/34640394
http://dx.doi.org/10.3390/jcm10194376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509704/
https://www.ncbi.nlm.nih.gov/pubmed/34640394
http://dx.doi.org/10.3390/jcm10194376

Ejemplares similares